{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-181885","form_type":"8-K/A","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2026-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.731778+00:00","generated_at":"2026-05-15T04:07:30.672717+00:00","sec_items":["2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"XOMA completes Generation Bio acquisition; estimates CVR value at $0.81/share","bullets":["XOMA paid $4.2913 per share cash plus one non-tradeable CVR for Generation Bio; ~70% of shares tendered.","CVR estimated at $0.81 per share, mainly from net cash above $29M; no value assigned to legacy assets.","Acquired ~$98M in Section 174 tax deductions and legacy LNP assets; no plans for preclinical development.","Moderna deal has up to ~$1.8B in milestones; next $7.5M milestone not expected within 12 months.","XOMA will use commercially reasonable efforts for 2 years to monetize legacy IP for CVR holders."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-181885","json":"https://secwatch.observer/filing/0001193125-26-181885.json","markdown":"https://secwatch.observer/filing/0001193125-26-181885.md","text":"https://secwatch.observer/filing/0001193125-26-181885.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312526181885/0001193125-26-181885-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312526181885/d229976d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:07:30.672717+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}